Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02297698
Title Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Cancer Insight, LLC
Indications

Her2-receptor positive breast cancer

Therapies

Sargramostim

Trastuzumab

E75

Age Groups: adult
Covered Countries USA


No variant requirements are available.